Anchor Balloon

Executive Summary

Anchor Balloon is a private medical device company developing a novel angioplasty balloon platform that incorporates a guidewire anchoring mechanism to enhance device advancement and stability during vascular interventions. Founded in 2018 and headquartered in Santa Clara, California, the company’s initial focus is on the cardiovascular market, where its technology aims to address procedural challenges such as balloon slippage and difficult lesion crossing. By securing the balloon relative to the guidewire, the design potentially improves precision and reduces complications in percutaneous coronary interventions. The platform’s versatility also suggests applicability in neurointervention, interventional radiology, and other endovascular procedures, broadening its addressable market. The company is at an early stage, with no disclosed funding rounds or regulatory clearances to date. Its success hinges on achieving key milestones, including preclinical validation, first-in-human studies, and FDA clearance. The cardiovascular angioplasty market is well-established but competitive, with major players like Medtronic and Boston Scientific. Anchor Balloon’s differentiation lies in its anchoring mechanism, which could provide a meaningful clinical advantage. However, as a private startup, it faces typical risks of capital constraints, regulatory hurdles, and adoption challenges. Conviction is moderate, reflecting uncertainty around execution and market entry.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing70% success
• TBDFirst-in-Human Study Initiation40% success
• TBDFDA 510(k) Submission for Cardiovascular Indication30% success